Expert panel updates clinical guidelines for CAR T-cell therapy in autoimmune conditions

An international consortium of 31 experts published updated recommendations for using CAR T-cell therapy to treat severe autoimmune diseases that have not responded to standard treatments. The new framework covers multiple disease types including rheumatological, neurological, and pediatric autoimmune conditions and provides guidance on patient selection, diagnostic assessment, and clinical management. The update reflects growing clinical experience with CAR T-cell applications beyond cancer, though experts emphasize this remains an evolving field requiring treatment in experienced, accredited centers.

CAR T-cell therapy, previously developed for cancer treatment, involves genetically modifying a patient's immune cells to recognize and attack disease-causing targets. The 2026 update builds on initial guidance from 2024, reflecting accelerated clinical adoption across multiple disease categories. The framework addresses the complexity of autoimmune conditions, where the immune system mistakenly attacks healthy tissue, requiring specialized assessment to distinguish treatment side effects from disease progression.

The consensus emphasizes accreditation and multidisciplinary collaboration because autoimmune diseases present highly variable presentations across different organ systems and patient backgrounds. Long-term monitoring protocols and systematic data collection are prioritized to establish a stronger evidence foundation, as clinical experience with this application remains relatively recent compared to oncological uses.